Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

Trial Profile

A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Chemotherapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2018

At a glance

  • Drugs Enfortumab vedotin (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pembrolizumab
  • Indications Urogenital cancer
  • Focus Adverse reactions
  • Acronyms EV103
  • Sponsors Astellas Pharma Global Development
  • Most Recent Events

    • 16 Nov 2018 Single group assignment has changed to sequential. Number of treatment arms and planned patient number has increased.
    • 16 Nov 2018 Planned number of patients changed from 85 to 159.
    • 16 Nov 2018 Planned End Date changed from 1 Sep 2020 to 1 Sep 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top